The clinically relevant conclusions that can be drawn suggest that heterogeneity with respect to pathway activity within a single biopsy may generally be representative for the whole tumor, with the possible exception of the PI3K pathway, while variation in ER pathway activity is relatively small within the PT compared to that seen between luminal breast cancers from different patients. This evidence concerns the gene ESR1 and neoplasm.